Edgewise Therapeutics (NASDAQ:EWTX) Stock Breaks Above 50-Day Moving Average After Analyst Downgrade

Key Points

• Edgewise shares crossed above their 50-day moving average after Wall Street Zen upgraded its rating from Sell to Hold. The stock traded as high as $45.76 and last stood at $45.04, compared with a 50-day average of $40.86.
• Analyst sentiment remains broadly positive: nine analysts rate the stock Buy, one Hold and two Sell, for a MarketBeat consensus of Moderate Buy and a $52.83 average price target.
• Near-term attention includes an unconfirmed report of takeover interest and favorable FDA feedback on the Phase 3 plan for EDG-7500; the company says its STRATUS-HCM program is on track to begin in Q4 2026.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Friday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The stock has a 50-day moving average of $40.86 and traded as high as $45.76. Edgewise Therapeutics shares last traded at $45.04, with a volume of 3,711,351 shares traded.

Other research analysts have also issued reports about the stock. Royal Bank Of Canada boosted their target price on shares of Edgewise Therapeutics from $48.00 to $59.00 and gave the company an "outperform" rating in a research note on Wednesday, June 17th. Guggenheim lifted their price objective on Edgewise Therapeutics from $41.00 to $51.00 and gave the company a "buy" rating in a report on Monday, July 6th. HC Wainwright upped their price target on Edgewise Therapeutics from $45.00 to $57.00 and gave the company a "buy" rating in a research note on Monday, September 21st. The Goldman Sachs Group raised their price target on shares of Edgewise Therapeutics from $32.00 to $36.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 11th. Finally, JPMorgan Chase & Co. increased their price target on Edgewise Therapeutics from $53.00 to $60.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $52.83.

Insider Buying and Selling

In other Edgewise Therapeutics news, CEO Kevin Koch sold 17,971 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $43.68, for a total transaction of $784,973.28. Following the completion of the transaction, the chief executive officer owned 52,488 shares in the company, valued at $2,292,675.84. This trade represents a 25.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Joanne Donovan sold 6,522 shares of Edgewise Therapeutics stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $43.85, for a total transaction of $285,989.70. Following the sale, the chief marketing officer owned 11,544 shares of the company's stock, valued at $506,204.40. The trade was a 36.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,329 shares of company stock valued at $1,675,529 in the last 90 days. Corporate insiders own 21.30% of the company's stock.

Edgewise Therapeutics News Roundup

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: A report of takeover interest appears to be the main near-term catalyst behind the stock’s rise. The report does not establish that a deal has been agreed or that a transaction will occur. Edgewise Therapeutics gains amid report of takeover interest
• Positive Sentiment: The FDA gave favorable feedback on EDG-7500’s Phase 3 plan following an end-of-Phase 2 meeting. The STRATUS-HCM program is designed to study obstructive and nonobstructive HCM and is on track to begin in Q4 2026, reducing uncertainty around the development path. FDA meeting and Phase 3 update
• Neutral Sentiment: Wedbush cut its price target to $51 from $53 but kept an Outperform rating, leaving its view positive despite the modest reduction. Wedbush lowers EWTX price target
• Neutral Sentiment: Edgewise reported quarterly EPS of $9.65, well above the consensus estimate of a loss of $0.53. The unusually large reported figure may need context to assess its relevance to ongoing operations.
• Negative Sentiment: Put-option purchases were unusually high, with 2,813 contracts traded—279% above typical volume. This may reflect increased hedging or bearish positioning, though options activity alone does not confirm investor expectations.

Hedge Funds Weigh In On Edgewise Therapeutics

Several institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC raised its holdings in shares of Edgewise Therapeutics by 64.9% during the 1st quarter. Parallel Advisors LLC now owns 1,032 shares of the company's stock valued at $33,000 after purchasing an additional 406 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Edgewise Therapeutics by 26.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,666 shares of the company's stock worth $108,000 after purchasing an additional 559 shares during the period. AlphaCentric Advisors LLC raised its holdings in Edgewise Therapeutics by 4.6% in the 3rd quarter. AlphaCentric Advisors LLC now owns 16,572 shares of the company's stock valued at $673,000 after acquiring an additional 732 shares in the last quarter. KBC Group NV bought a new position in Edgewise Therapeutics in the first quarter worth $49,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Edgewise Therapeutics by 10.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,216 shares of the company's stock valued at $792,000 after acquiring an additional 1,843 shares in the last quarter.

Edgewise Therapeutics Stock Performance

The firm has a 50 day moving average price of $40.86 and a two-hundred day moving average price of $36.54. The company has a market capitalization of $4.89 billion, a P/E ratio of 5.50 and a beta of 0.39.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $9.65 EPS for the quarter, beating the consensus estimate of ($0.53) by $10.18. On average, equities analysts expect that Edgewise Therapeutics, Inc. will post -2.09 earnings per share for the current year.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule therapies for severe muscle disorders. The company's research programs target the biology of skeletal and cardiac muscle, with the goal of addressing diseases for which treatment options remain limited.

Edgewise's lead product candidate is sevasemten (formerly EDG-5506), an oral therapy designed to reduce contraction-induced muscle damage associated with dystrophinopathies, including Duchenne and Becker muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.